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Original Article
Sexual dysfunctions, such as reduced libido or arousal 
and impairments in erectile, ejaculatory, and orgasmic 
functions, are commonly reported in men among both the 
mentally ill as well as the healthy populations. The preva-
lence of sexual dysfunction among healthy men ranges 
from 20% to 35%, and in male populations with psychi-
atric illness, 50% to 65%. (Grube & Weigand-Tomiuk, 
2002; Laumann, Paik, & Rosen, 1999; Macdonald et al., 
2003; Oksuz & Malhan, 2005; Rosen, 2000).
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Abstract
Methadone is largely recognized as an effective treatment for opiate-dependent patients; however, it causes reduced 
brain dopaminergic action resulting in significant sexual dysfunction. Bupropion is a dopamine reuptake inhibitor which 
can potentially improve erectile function among male patients on methadone (MMT). This is a phase II, randomized, 
double-blind, parallel-group, placebo-controlled trial, involving 80 MMT male patients (73.4%) with mean age of 42.83 
years ±9.68. These MMT male patients were randomly assigned into two groups to receive bupropion and placebo, 
respectively. The primary efficacy outcome measure was the difference between the two groups in end-point mean 
improvement scores using the measurement of Clinical Global Impression Scale adapted for Sexual Function (CGI-
SF) at baseline (week 0) and at weeks 2, 4, and 6. Malay version of the sexual desire inventory-2 (SDI-2-BM) and 
Malay version of International Index of Erectile Function 15 (Mal-IIEF-15) domain scores were evaluated as secondary 
parameters. Improvement of the end-point mean from baseline were seen across the scores of SDI-2-BM (mean 
difference = 11.77 ± 2.90, 95% confidence interval (CI) [3.89, 19.54], p < .001) and Mal-IIEF-15 (mean difference = 
8.37 ± 2.71, 95% CI [15.75, 0.99], p = .02), and the total plasma testosterone level (mean difference = 4.03, 95% CI 
[0.90, 7.15], p = .01). A categorical improvement of “much/very much improved” (CGI-SF score = 2) was reported 
by 58.3% (n = 21/36) of bupropion SR-assigned versus 27.7% (n = 10/36) placebo-assigned patient. Bupropion was 
well tolerated with no serious adverse events reported other than insomnia (17.7%). Six weeks of bupropion SR 
treatment reported significant improvement in key aspects of sexual function among male opiate-dependent patients 
on methadone maintenance treatment with emergent sexual dysfunction.
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Methadone maintenance treatment (MMT) is a com-
prehensive treatment program that involves the long-term 
prescribing of methadone as a substitution therapy for 
opiate dependence. Despite the effectiveness of the meth-
adone maintenance therapy (Mattick, Breen, Kimber, & 
Davoli, 2009), the meta-analytical pooled prevalence for 
sexual dysfunction among methadone users was 52% 
(95% confidence interval (CI) [0.39, 0.65]), whereby the 
hypoactive sexual desire and low libido were the most 
prevalent sexual dysfunctions (Yee, Loh, & Ng, 2014). 
Previous studies reported that sexual dysfunction 
decreased quality of patient’s sexual life (Brown, 
Balousek, Mundt, & Fleming, 2005) and damaged inti-
mate relationships, while at the same time increased the 
risk of dropout from methadone maintenance therapy 
prematurely (Hallinan et al., 2008). Management for 
methadone-induced sexual dysfunction remains a chal-
lenge for the physicians because by reducing or stopping 
of methadone in this group of patients may not be always 
possible. Some of the ex-opiate-dependent patients 
relapsed after their methadone dosage became too low. 
Moreover, some of them used other illicit drugs, espe-
cially stimulants, to boost up their sex function (La Pera 
et al., 2008). Hence, the physicians need other strategies 
to manage sexual dysfunction in this group of patients.
Methadone is a slow-and-long acting opiate agonist 
that causes the stimulation of mu (µ) opiate receptors in 
various areas of the brain. There are few hypotheses that 
try to explain the effect of methadone on sexual dysfunc-
tion. One of the oldest hypotheses revealed that metha-
done alters the function of tubero-infundibular and 
hypothalamus-pituitary-gonadal (HPG) axis through 
dopaminergic pathway by chronic stimulation of the μ 
opiate receptors. Hence, the reduced neurotransmitter 
dopamine secretion causes disinhibition of prolactin pro-
duction, which subsequently exerts a negative effect on 
the gonadotrophin releasing hormone (GnRH). This 
action lowers the level of sex hormones, particularly tes-
tosterone, which then causes low sexual desire and inter-
ests (Balon & Segraves, 2005). However, in a recent 
meta-analysis (Yee, Loh, Hashim, et al., 2014), the pro-
lactin level was reported to be not statistically signifi-
cantly associated with sexual dysfunction in the 
methadone group. Therefore, this hypothesis could not 
explain the sexual dysfunction in this group of patients.
Previous studies have demonstrated that opioids, both 
endogenous and exogenous, led to a decline in luteinizing 
hormone (LH), follicle-stimulating hormone (FSH) from 
the pituitary gland, and testosterone or estradiol (E2) 
from the gonads (Daniell, 2002; Hallinan et al., 2009; 
Vuong, Van Uum, O’Dell, Lutfy, & Friedman, 2010). de 
la Rosa and Hennessey (1996) suggested that opioids 
decreased testosterone level in men, either by altering the 
release of normal pulsatility of GnRH or affecting the 
response of the anterior pituitary to GnRH. Previous stud-
ies also reported that opioids may also have direct effects 
on the pituitary gland and the testes which resulted in low 
serum testosterone concentrations and caused symptoms 
of testosterone deficiency (De Maddalena, Bellini, Berra, 
Meriggiola, & Aloisi, 2012; Vuong et al., 2010). The clin-
ical manifestations of testosterone deficiency included 
significant decreases in sexual desire, erectile dysfunc-
tion, delayed ejaculation, depressive mood and irritability 
(Buvat, Maggi, Guay, & Torres, 2013).
Another well-known hypothesis was the interplay 
effects of excitation and inhibition sexual systems in the 
brain. Brain dopamine in the hypothalamic and mesolim-
bic systems appears to form the core of sexual excitatory 
system. In contrast, brain opiate, endocannabinoid, and 
serotonin systems are activated during periods of sexual 
inhibition, and blunt the ability of excitatory systems 
(Pfaus, 2009). Animal studies (Coolen, Fitzgerald, Yu, & 
Lehman, 2004; van Furth, van Emst, & van Ree, 1995; 
Vuong et al., 2010) reported that opioids have significant 
suppressive effects on sexual behavior, which appear to 
be modulated primarily via activation of μ- and δ-
receptors in the medial preoptic area and the ventrome-
dial hypothalamus. A recent imaging study identified that 
the methadone maintenance patients had reduced dopa-
mine receptor 2 (D2) in various parts of their brains, with 
consequences of reduced brain dopaminergic function 
(Gradin, Baldacchino, Balfour, Matthews, & Steele, 
2013). Some researchers ( Salehi et al., 2015; Tatari, 
Shakeri, Farnia, Heidari, & Rezaei, 2013) proposed to 
use dopamine reuptake inhibitor such as bupropion to 
treat sexual dysfunction in this group of patients. There 
was an open-labeled, quasiexperimental study done by 
Tatari et al. in 2013 (Tatari et al., 2013), whereby 100 mg 
of bupropion was administered for 6 weeks on 67 metha-
done maintenance men who had erectile dysfunction. In 
this study, bupropion significantly improved the erectile 
function in this group of patients (International Index of 
Erectile Function score improved from 12.79 ± 1.37 to 
15.94 ± 2.14). The sample size of that study was small 
and had many methodological limitations.
The main objective of this research was to determine 
the therapeutic effect of bupropion hydrochloride sus-
tained-release in the treatment of methadone emergent 
sexual dysfunction in men.
Materials and Methods
Study Design and Population
This phase II, randomized, double-blind, parallel-group, 
placebo-controlled trial was conducted from December 
2015 to December 2017 in University Malaya Medical 
Center (UMMC) and University Malaya Center of 
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Addiction Science Studies (UMCAS). This study was 
approved by the Medical Ethics Committee of University 
Malaya Medical Center (UMMC, Kuala Lumpur, 
Malaysia, NO: 20154-1212) and National Medical 
Research Register (NMRR, No: NMRR-15-303-24854). 
This study was conducted according to the Declaration of 
Helsinki, and registered at the ClinicalTrials.gov with the 
following number: NCT02593396.
All the male subjects who attended the methadone 
maintenance clinic were approached. Screening data 
were reviewed to determine subject eligibility. Subjects 
who met all inclusion criteria and none of the exclusion 
criteria were recruited into the study. The inclusion cri-
teria included: (a) they were aged from 18 to 60 years; 
(b) had a diagnosis of opiate dependence based on 
Diagnostic and Statistical Manual of Mental Disorders, 
Fifth Edition (DSM-5) criteria; (c) they were taking a 
stable dose of methadone for ≥6 months; (d) they were 
experiencing constant sexual dysfunction for ≥4 weeks 
receiving MMT; (e) they were in a stable sexual rela-
tionship for ≥6 months. The exclusion criteria were: (a) 
the subjects exhibited severe behavior disturbances or 
psychotic symptoms; (b) obvious organic illnesses 
which caused the sexual dysfunction (such as patients 
with diabetes, heart disease, or vascular disease); (c) 
those with history of sexual dysfunction before metha-
done therapy; (d) those who were receiving antiviral 
treatment for viral hepatitis or HIV; (e) those who were 
receiving androgen replacement treatment, phosphodi-
esterase type 5 inhibitors (PDE5i), or any traditional 
sexual enhancement remedies; (f) those with a history 
of an eating disorder (e.g., anorexia, bulimia) or sei-
zures (e.g., epilepsy); (g) those who fulfilled other axis 
1 diagnoses (e.g., Bipolar disorder) base on DSM-5; (h) 
or those who were using other psychotropic medica-
tions other than methadone; (i) QTc prolongation >450 
ms in the electrocardiogram; (j) those who refused to 
participate.
All patients gave their written informed consent 
before study procedures began. At the baseline, the 
patients were assessed by using the Opiate Treatment 
Index (OTI), Malay Version of the Golombok-Rust 
Inventory of Marital State (Mal-GRIMS), the Malay ver-
sion of the self-rated Montgomery-Asberg Depression 
Rating Scale (MADRS-BM), Malay version of the 
Fagerstrom Test for Nicotine Dependence (FTND-M), 
Malay version of International Index of Erectile Function 
15 (Mal-IIEF-15), the Malay version of the sexual desire 
inventory-2 (SDI-2-BM), and Clinical Global Impression 
Scale adapted for Sexual Function (CGI-SF). Besides, 
all patients received a physical examination, including 
body mass index (BMI), blood pressure, 12-lead electro-
cardiogram, rapid urine drug test for opiate (non-metha-
done), marijuana, methamphetamine, and ecstasy. Blood 
samples were obtained from all study participants and 
assayed for prolactin and total testosterone in a single 
laboratory.
After a diagnostic screening and baseline visit, eligible 
patients were randomly and double-blindly assigned to 
either receiving the Bupropion Hydrochloride Sustained-
Release (Bupropion SR) 150 mg twice daily (n = 40) or a 
placebo (Calcium Lactate) 300 mg twice daily (n = 40), 
in a 1:1 ratio using a computer-generated table of random 
numbers using the Randomization.com program. 
Investigators and patients were both blinded to the alloca-
tion of the study drug throughout the study period. A non-
blind physician had access to the study randomization list 
so that he could provide appropriate follow-up care to 
patients who dropped out of the study.
All study medications were repacked in sealed opaque 
packets and dispensed by the research assistant who was 
not involved in the assessment of the study. All study 
medications were packaged in sets of 11 (1 tablet per day 
for 3 days, followed by 2 tablets per day for 4 days) for 
the first week. Subsequently, all study medications were 
packaged in sets of 14 (2 tablets per day for 7 days). All 
study medications were identical both in their color and 
shape, and they were kept in sealed opaque packets before 
inserted into sealed envelopes.
All patients were assessed biweekly by a consultant 
psychiatrist (A Yee) using CGI-SF, SDI-2-BM, Mal-
IIEF-15, MADRS-BM, and FTND-M. Additionally, any 
treatment-related emergent side effects were all recorded 
and documented. All the data were analyzed by a statisti-
cian who was also blinded to the allocation of the study 
drugs.
Efficacy Criteria
The primary efficacy outcome measure was the differ-
ence between the two groups in end-point mean improve-
ment scores using the measurement of CGI-SF at baseline 
(week 0) and at weeks 2, 4, and 6. SDI-2-BM and Mal-
domain scores were evaluated as secondary parameters.
Main Outcome Measurements
CGI-SF. This is a clinician-rated severity and improve-
ment scale adapted from the CGI Scale (Guy, 1976). This 
scale assesses the changes of the sexual function from 
baseline to weeks 2, 4, and 6 (final or last visit) with 
anchored scores from 1 (normal/very much improved) to 
7 (most extreme sexual dysfunction/very much worse). 
Lower scores indicate better sexual functioning.
SDI-2-BM. This is a self-assessment of sexual desire in 
cognitive terms. This scale contains 14 items which yield 
two domain scores: dyadic sexual desire (DSD) and 
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solitary sexual desire (SSD) (Spector, Carey, & Steinberg, 
1996). DSD is defined as individuals’ desire for intimacy 
with another person and SSD is defined as individuals’ 
desire in engaging sexual behavior by oneself. For all the 
questionnaire items, respondents rate their sexual desire on 
an 8-point Likert scale except for items 1, 2, and 10, which 
are only rated on a 7-point Likert scale. DSD consists of 8 
items and SSD consists of 3 items. All items are summed 
up to dictate the total sexual desire. Higher scores reflect 
higher sexual desire. The total possible sores for DSD 
range from 0 to 62, and for SSD, range from 0 to 23 (Spec-
tor et al., 1996). This instrument was validated in Malay 
version (SDI-2-BM) with good internal consistency (DSD, 
Cronbach’s α = 0.93 and SSD, Cronbach’s α = 0.88) (Yee 
et al., in press).
Mal-IIEF-15. IIEF-15 is a 15-item, multidimensional self-
reporting instrument for the evaluation of five distinct 
domains of the male sexual function for the past 4 weeks 
(Rosen, Cappelleri, Gendrano, & Correspondence, 2002). 
The five domains include erectile function (items 1, 2, 3, 
4, 5, and 15), orgasmic function (items 9 and 10), sexual 
desire (items 11 and 12), intercourse satisfaction (items 6, 
7, and 8), and overall satisfaction (items 13 and 14). Each 
item has a score ranging from 0 to 5 with higher score 
reflecting a better sexual function. Mal-IIEF-15 has been 
validated among Malaysian male population with Cron-
bach’s α value of 0.74 and intra-class correlation coeffi-
cient is of 0.59 (Quek, Low, Razack, Chua, & Loh, 2002).
Other Measurements
OTI
OTI is a multidimensional, structured interview for the 
evaluation of methadone treatment. It assesses five inde-
pendent outcome domains including drug use, HIV risk-
taking behavior, social functioning, criminality, and 
health status. The drug use domain is examined by calcu-
lating Q score for each drug class. A Q score is a score 
which is the adding the number of use episodes and 
divided by the total of the two intervals between use. The 
higher the value of “Q” indicated the heavier the drug 
usage. In other domains, all the questions are ranged from 
0 (good) to 5 (worse) Likert scale. The total score for 
each domain was derived by adding up the scores for 
each question. Higher scores reflect greater degree of 
dysfunction in that domain (Darke, Ward, Hall, Heather, 
& Wodak, 1991).
Malay Version of the Golombok-Rust Inventory 
of Marital State
The Golombok Rust Inventory of Marital State (GRIMS) 
is a new short (28 items) questionnaire for the assessment 
of the quality of a relationship (Rust, Bennun, Crowe, & 
Golombok, 1986). Each item is answered on a four-point 
scale from strongly agree, agree, disagree, and strongly 
disagree. A total score is computed (range 0–84), with a 
high score indicating problematic marital relationship. In 
this study, this instrument was used to detect the marital 
satisfaction in this group of participants. GRIMS has 
been validated in Malay with excellent internal consis-
tency (Cronbach’s α = 0.43 to 1.00), good test–retest cor-
relation coefficient and intra-class correlation coefficient 
(ICC = 0.51 and above), high sensitivity and specificity 
(Quek, Low, Razack, Loh, & Chua, 2001).
MADRS-BM
MADRS-S is a 9-item self-report measure of depression 
developed by Svanborg and Asberg (Svanborg & Åsberg, 
1994). Participants rate items on a 4-point Likert scale 
ranging from 0 (no depressive symptoms) to 3 (worst 
depressive symptoms). Possible score ranges from 0 to 
27, with higher scores indicating greater symptom sever-
ity. The MADRS-BM was validated and exhibited good 
internal consistency with Cronbach’s α of 0.78 among 
Malaysians (Yee, Yassim, Loh, Ng, & Tan, 2015).
FTND-M
FTND-M is a self-report questionnaire in Malay language 
to assess the nicotine dependence among the smokers. 
FTND-M consists of 6 items and has similar internal con-
sistency with the original FTND (Anne Yee, Ng, & Rusdi, 
2011). The total score ranges from 0 to 10 with higher 
score indicating more severe nicotine dependence.
Data Analysis
A sample size of 66 patients (33 per group) was expected 
to detect a significant difference in sexual dysfunction 
with 90% power for a type I error rate of α = 0.05 
between bupropion and placebo. Assuming 20% attri-
tion, 80 patients were entered. Statistical significance 
was set at p < .05.
The χ2 or the Fisher’s exact test for categorical vari-
ables were used to test group differences (bupropion SR 
and placebo) at baseline. For continuous variable, Mann–
Whitney U test (nonparametric distribution) and t test 
(parametric distribution) were used to test the baseline 
differences between bupropion SR and placebo.
Intention-to-treat (ITT) analyses were used for all effi-
cacy variables and included all patients who had been 
randomized, took at least 1 dose of study trial medication 
and had at least one efficacy assessment after the baseline 
visit. The safety population included all patients who 
took at least one dose of study medication. A case-wise 
interpolation was used to replace missing values. The 
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changes in sexual functioning measured by CGI-SF, SDI-
2-BM, and Mal-IIEF-15 from baseline to each patient’s 
own end-point were the dependent measures of efficacy. 
A two-way repeated measures analysis of covariance was 
used to determine study group (bupropion SR and pla-
cebo) in the change from baseline to end-point for the 
measures of efficacy and sexual functioning (time × 
group interaction). Pairwise comparisons using 
Bonferroni adjustment correction of all sexual-function-
ing variables were performed between bupropion SR and 
placebo group across the time.
The safety population consisted of all patients who 
consumed at least 1 dose of study trial medication and 
after baseline measurement. Adverse events were com-
pared between groups using frequency counts. SPSS v. 
23 (IBM Corp, Armonk, NY) used for data analysis.
Results
This study screened 109 and included 80 (73.4%) male 
patients aged 25–60 (mean age 42.83 years ±9.68) who 
met all inclusion criteria and none of the exclusion crite-
ria. A total of 80 men were randomly assigned to receive 
bupropion SR (n = 40) or placebo (n = 40). They had been 
taking 70.44 ± 29.01 mg methadone for 46.09 ± 29.5 
months. There were no statistically significant differ-
ences between baseline demographics in the assigned 
treatment groups (Table 1).
Systematic review for any protocol deviations in 
patient enrollment was undertaken before unblinding. 
The 72 randomized men constituted the ITT analysis. 
Fifty-one men (63.8%) completed the study: with 65% 
(26 of 40) in the bupropion SR and 62.5% (25 of 40) in 
the placebo group completed the 6-week study. Three 
men in the placebo group and none in bupropion SR 
group discontinued prematurely for lack of efficacy 
(Figure 1).
Efficacy Measures
CGI-SF
The difference from baseline to end-point in the mean ± 
SD change in the Clinical Global Impression scale sexual 
function improvement by intent-to-treat analyses was 5.33 
± 0.48 to 2.64 ± 1.61 with a difference of 2.57 (95% CI 
[1.87, 3.28]) for the bupropion SR group versus 5.25 ± 
0.60 to 3.75 ± 1.59 with a difference of 1.62 (95% CI [0.91, 
2.33]) for the placebo group, which showed a significant 
difference of 0.83 (95% CI [−1.5, −1.30], p = .02) between 
groups (Figure 2; Table 2). A categorical improvement of 
“much/very much improved” (CGI-SF score ≤2) was 
reported by 58.3% (n = 21/36) of bupropion SR-assigned 
versus 27.7% (n = 10/36) placebo-assigned patient.
SDI-2-BM
At end-point, total SDI-2-BM scores improved from 
baseline in bupropion SR group (mean difference = 11.77 
± 2.90, 95% CI [3.89, 19.54], p < .001) when compared 
to those in placebo group (Table 2). DSD scores improved 
from baseline for patients receiving bupropion SR (mean 
difference = 9.41 ± 1.82, 95% CI [4.46, 14.35], p < .001) 
compared with those receiving placebo (mean difference 
= 2.81 ± 0.36, 95% CI [−2.14, 7.76], p = .76) (Table 3 and 
Figure 3). SSD scores between bupropion SR and control 
group were statistically not significant.
Mal-IIEF-15
At end-point, the total Mal-IIEF-15 mean scores improved 
from baseline for patients receiving bupropion SR (mean 
difference = 8.37 ± 2.71. 95% CI [15.75, 0.99], p = .02) 
compared with those receiving placebo (mean difference 
= 4.19 ± 2.71, 95% CI [10.43, 5.12], p = .76) (Table 2; 
Figure 4). Patients receiving bupropion SR showed sig-
nificant improvements from baseline to end-point on 
IIEF domains of erectile function (mean difference = 
3.93, p = .04) and sexual desire (mean difference = 1.68, 
p < .001) but not in patients receiving placebo (Table 3).
Plasma Testosterone and Prolactin Levels
At end-point, the total plasma testosterone improved 
from baseline in bupropion SR group (mean difference = 
4.03, 95% CI [0.90, 7.15], p = .01) when compared to 
those in the placebo group (mean difference = 3.32, 95% 
CI [0.07, 6.57], p = .05). There were no statistically sig-
nificant differences in plasma testosterone levels between 
the two groups.
There was no improvement noted in plasma prolactin 
levels from baseline to end-point in bupropion SR or pla-
cebo group. There were also no statistically significant 
differences in prolactin levels between the two groups.
Adverse Events
The most common adverse event was insomnia, reported 
by 17.7% (n = 6) of men taking bupropion SR and 2.8% 
(n = 1) taking placebo (p = .11). Less frequent were skin 
rash, 8.3% (n = 3) versus 0% (p = .24); inability to concen-
trate, 5.6% (n = 2) versus 0% (p = .49); constipation, 5.6% 
(n = 2) versus 5.6% (n = 2) (p = .61); and headache, 2.8% 
(n = 1) versus 2.8% (n = 1) (p = .49), respectively. More 
common adverse events in the placebo group than in the 
bupropion SR group were ineffectiveness 8.3% (n = 3) 
versus 0% (p = .24), nausea 5.6% (n = 2) versus 0% (p = 
.49) and loss of appetites, 2.8% (n = 1) versus 0% (p = 
1.00), respectively. Nine patients treated with bupropion 
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Table 1. Baseline Sociodemographic, Treatment Characteristics, and Sexual Function of All Male Participants.
Variables Bupropion (n = 40) Placebo (n = 40) df χ2, z, t p value
Age, years, mean ± SD 42.30 ± 9.49 43.50 ± 10.09 78 0.55 .62
Daily dose, mg, mean ± SD 71.67 ± 28.57 69.25 ± 29.75 78 −0.37 .71
Duration of MMT, months, mean ± SD 50.03 ± 32.46 42.25 ± 26.15 78 −1.17 .24
BMI, mean ± SD 25.83 ± 5.91 24.47 ± 4.74 78 −1.13 .26
SBP, mean ± SD 130.43±15.89 135.43±18.79 78 1.29 .20
DBP, mean ± SD 80.25 ± 10.79 81.63 ± 9.39 78 0.61 .54
QTc, ms, mean ± SD 428.60 ± 24.51 426.90 ± 26.90 78 −0.29 .77
Prolactin, μIU/ml, 
mean ± SD
181.69 ± 118.47 194.96 ± 122.98 78 0.42 .68
Total testosterone (nmol/L) 
(ng/dl)
8.72 ± 5.98 10.56 ± 5.98 78 1.37 .18
Ethnic group, n (%)
 Malay 34 (85.0) 34 (85.0) 3 2.50 .54
 Chinese 3 (7.5) 5 (12.5)  
 Indian 1 (2.5) 1 (2.5)  
 Others 2 (5.0) 0 (0)  
Religion, n (%)
 Islam 36 (90.0) 34 (85.0) 3 1.20 .64
 Christianity 0 (0) 1 (2.5)  
 Buddhism 3 (7.5) 4 (10.0)  
 Hinduism 1 (2.5) 1 (2.5)  
Education level, n (%)
 No formal education 0 1 (2.5) 3 1.11 .77
 Primary 3 (7.5) 3 (7.5)  
 Secondary 32 (80.0) 32 (80.0)  
 Tertiary 5 (12.5) 4 (10.0)  
Employment, n (%) 36 (90.0) 35 (87.5) 1 0.13 1.00
Family history of drug use, n (%) 6 (15.4) 7 (17.9) 1 0.09 1.00
HBV, n (%) 1 (2.5) 1 (2.5) 1 0 1.00
HCV, n (%) 12 (30.0) 12 (30.0) 1 0.24 .81
Total FTND scorea, 
mean ± SD
2.95 ± 2.19 4.70 ± 5.63 72 −1.69 .09
OTI, mean ± SD
Q scores of drugs usea
 Tobaccoa 11.79 ± 9.04 9.63 ± 6.96 78 −0.88 .38
 Alcohola 0.05 ± 0.316 0 78 −1.00 .32
 Marijuanaa 0 0.0005 ± 0.003 78 −1.00 .32
 Amphetaminesa 0.002 ± 0.009 0.0009 ± 0.005 78 −0.47 .64
 Heroina 0.0008 ± 0.005 0.03 ± 0.16 78 −1.03 .30
HIV risk-takinga 5.85 ± 2.23 4.87 ± 2.93 78 −1.57 .12
Criminality 0 0 −  
Social functioninga 8.45 ± 4.81 8.20 ± 4.75 78 −0.04 .97
Healtha 1.43 ± 1.08 1.15 ± 0.74 78 −0.69 .49
Total Mal-GRIMS score, 
mean ± SD
46.63 ± 5.25 47.65 ± 5.40 78 0.75 .46
Total MADRS-BM scorea, mean ± SD 2.68 ± 3.59 3.53 ± 4.44 78 0.92 .36
Mal-IIEF-15 domain, mean ± SD
 Erectile function 17.15 ± 9.28 18.15 ± 7.73 78 0.52 .69
 Orgasmic functiona 6.17 ± 3.21 5.44 ± 3.29 78 −1.00 .32
 Sexual desire 5.38 ± 1.78 5.74 ± 1.57 78 0.98 .33
 Intercourse satisfaction 6.75 ± 4.01 6.59 ± 3.87 78 −0.18 .86
 Overall satisfaction 6.35 ± 2.67 6.51 ± 2.37 78 0.29 .78
 Total 41.80 ± 19.13 42.44 ± 16.43 78 0.16 .88
(continued)
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Variables Bupropion (n = 40) Placebo (n = 40) df χ2, z, t p value
SDI-2-BM, mean ± SD
 DSD 27.48 ± 9.76 29.62 ± 10.24 78 0.95 .35
 SSD 6.20 ± 4.27 4.54 ± 4.57 78 −1.67 .10
 Total 42.58 ± 14.97 42.87 ± 15.83 78 0.09 .93
CGI-S score 5.35 ± 0.48 5.25 ± 0.54 78 −0.87 .57
Note. aBased on Mann–Whitney test. MMT = methadone maintenance treatment; BMI = body mass index; HBV = hepatitis B; HCV = hepatitis 
C; OTI = Opioid Treatment Index; Mal-GRIMS = Malay Version of the Golombok-Rust Inventory of Marital State; MADRS-BM = Malay 
version of self-rated Montgomery-Asberg Depression Rating Scale; Mal-IIEF-15 = Malay version of the International Index of Erectile Function 
15; SDI-2-BM = Malay version of the sexual desire inventory-2; DSD = dyadic sexual desire; SSD = solitary sexual desire; CGI = clinical global 
impression-severity; df = degrees of freedom; SD = standard deviation; t = t test; χ2 = chi-square test; z = z test; nmol/L = nanomoles per 
liter; ng/dl = nanograms per deciliter; μIU/ml = macro international units per milliliter.
*p < .05. **p < .01.
Table 1. (continued)
Figure 1. CONSORT flow diagram for evaluation of bupropion efficacy on sexual dysfunction among male patients on 
methadone maintenance therapy: A double-blind placebo-controlled trial.
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SR and 8 patients treated with placebo discontinued the 
study prematurely because of adverse events, mainly 
insomnia (Table 4). No patient in any group had clinically 
significant changes in systolic and diastolic blood pres-
sure, and BMI. No serious adverse events related to trial 
medication were reported.
Discussion
To our knowledge, this is the first randomized trial to 
demonstrate a significant reduction in adverse sexual 
effects, measured by CGI-SF, SDI-2-BM, and Mal-
IIEF-15 that compared bupropion SR with placebo 
among men with methadone emergent sexual dysfunc-
tion, specifically low sexual desire while continuing sta-
ble-dose methadone treatment. A categorical improvement 
of “much/very much improved” in CGI-SF score was 
reported by 58.3% of bupropion SR-assigned versus 
27.7% (n = 10/36) placebo-assigned patients.
DSD scores improved from baseline for patients 
receiving bupropion SR with mean difference of 9.41 ± 
1.82 when compared with those receiving placebo. 
Besides, patients receiving bupropion SR showed signifi-
cant improvements from baseline to end-point on IIEF 
domains of erectile function (mean difference = 3.93, p = 
.04) and sexual desire (mean difference = 1.68, p <.001) 
but not in those receiving placebo. In addition, the total 
plasma testosterone also improved from baseline in 
bupropion SR group (mean difference = 4.03, 95% CI 
[7.15, 0.90], p < .01).
Hypoactive sexual desire is one of the major adverse 
effects for ex-heroin-dependent patients who are receiv-
ing methadone (Yee, Loh, & Ng, 2014). This could be 
one of the reasons MMT patients failed to comply with 
MMT. In current study, the patients who received bupro-
pion SR had shown statistically significant improvements 
from baseline to end of trial point on their DSD scores 
(<.001) and IIEF sexual desire domain scores (<.001). 
This finding is similar to the previous studies (Salehi 
et al., 2015; Tatari et al., 2013). This may indicate that 
bupropion SR, by blocking the reuptake of norepineph-
rine and dopamine, is able to alleviate the loss of sexual 
desire as a result of long-term methadone usage. The 
sexual desire pathway is an interplay between the sexual 
excitatory and inhibitory mechanisms in the brain. 
Dopamine is one of the main neurotransmitters which 
plays a major role in enhancing the sexual excitatory 
mechanism, while the endogenous opiate and methadone 
blunting it. Bupropion SR probably exerts effect on this 
dopamine-mediated enhancement of sexual excitatory 
mechanisms in the sexual desire pathway (Pfaus, 2009).
In this study, patients receiving bupropion SR showed 
significant improvements on IIEF domains of erectile 
function from baseline (mean = 18.14 ± 8.74) to end-
point (22.56 ± 7.69) but not in patients receiving pla-
cebo. In one local study, the prevalence of erectile 
dysfunction among MMT patients was up to 67% and 
the patients with depression were four times more likely 
to have erectile dysfunction than patients without 
depression (Teoh, Yee, Danaee, Ng, & Sulaiman, 2016). 
Given that bupropion SR is an effective amino-ketone 
antidepressant, along with the potential for improved 
erectile function, bupropion SR may serve as an attrac-
tive choice of treatment for MMT patients who have 
depression and also for those whose sexual dysfunction 
is a concern.
This study also identified that the total plasma testos-
terone had statistically significantly improved from 
baseline (mean = 7.98 ± 4.57) to end-point (mean = 
12.04 ± 8.46) in bupropion SR group but not in pla-
cebo group (p = .01). In contrast, this observation was 
not seen in the plasma prolactin. This has further proved 
that the effect of methadone on sexual function is pos-
sible through direct blocking of the dopamine-mediated 
release of gonadotrophin-releasing hormone rather than 
prolactin-releasing hormone at the hypothalamic-pitu-
itary-gonadal axis, resulting in decreased serum testos-
terone concentrations and symptoms of testosterone 
deficiency. Perhaps the addition of bupropion SR to 
ongoing MMT can ameliorate MMT-induced sexual 
dysfunction through the enhancement of activity of 
dopamine-mediate gonadotrophin releasing hormone, 
which in turn increases the level of plasma testosterone. 
Up to date, research on exploring the relationship 
between bupropion and testosterone levels remained 
scarce. In animal study (Bulmuş et al., 2015), serum tes-
tosterone levels were observed significantly higher in 
male rats receiving bupropion (47.74 ± 2.33 ng/ml) 
compared with control rats (39.69 ± 2.27 ng/ml, p < 
.05). Clayton et al. (2004) conducted 
Figure 2. Mean Clinical Global Impression Scale adapted 
for Sexual Function scores (CGI-SF) in methadone-emergent 
sexual dysfunction patients receiving sustained-release 
bupropion (bupropion SR) or placebo. *p < .05.
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a placebo-controlled, double-blind comparison of 
bupropion SR versus placebo in 42 patients with selec-
tive serotonin reuptake inhibitor (SSRI)-induced sexual 
dysfunction. Frequency of sexual activity was signifi-
cantly correlated to total testosterone level at baseline (r 
= .36, p = .027) and at week 4 (r = .41, p = .025) in this 
study. However, this study only consisted of 5 male 
patients, hence cautious interpretation must be carried 
out. Testosterone replacement therapy is one of the 
potential therapeutic options for sexual dysfunction 
where there is testosterone deficiency (Buvat et al., 
2013). Previous studies have demonstrated that testos-
terone replacement therapy improved sexual desire in 
men who have opioid-induced androgen deficiency 
(Basaria et al., 2015; Blick et al., 2012). However, the 
benefit of combination of testosterone replacement ther-
apy and bupropion SR to treat this condition remained 
uncertain. Furthermore, in current study, the total testos-
terone level also improved at placebo group (mean dif-
ference from baseline to weeks 6 is −3.32) and there 
were no statistically significant differences in plasma 
testosterone levels between the bupropion SR and pla-
cebo group at the end-point. Further research is needed 
to determine the effect of bupropion SR on plasma tes-
tosterone before any conclusion could be made.
Both bupropion and methadone are extensively 
metabolized by cytochrome P4502B6 (CYP2B6) in the 
human liver (Hedrich, Hassan, & Wang, 2016). Although 
bupropion has been reported to be a CYP2B6 inhibitor, 
CYP2B6 is highly polymorphic. Previous study identi-
fied CYP2B6*4, a variant of CYP2B6, to be an apparent 
rapid metabolizer phenotype. CYP2B6*4 increases 
methadone metabolism but decreases methadone con-
centrations, and demonstrates a particular susceptibility 
Table 2. Summary of All the Sexual Functioning Outcomes
Bupropion (n = 36) Placebo (n = 36) Mean EOT 
differencea
For bupropion 
vs. placebo
95% CI for 
differenceaBaseline EOT Baseline EOT
Outcome 
measure Mean ± SD Mean ± SD Mean ± SE
Lower 
bound
Upper 
bound
p 
value
CGI-SF 5.33 ± 0.48 2.64 ± 1.61 5.25 ± 0.60 3.75 ± 1.59 −0.83 ± 0.35* −1.5 −0.13 .02
SDI-2-BM
 DSD 26.19 ± 8.59 36.08 ± 10.17 27.67 ± 8.44 29.99 ± 13.44 5.83 ± 2.78* 0.28 11.37 .04
 SSD 6.22 ± 4.34 7.45 ± 4.97 5.06 ± 4.29 6.87 ± 5.97 0.58 ± 1.34 −2.09 3.24 .67
 Total 41.14 ± 14.00 53.53 ± 15.88 41.06 ± 14.12 47.36 ± 21.09 5.69 ± 4.41 −3.10 14.49 .20
Mal-IIEF-15 domain
 Erectile 
function
18.14 ± 8.74 22.56 ± 7.69 17.44 ± 8.07 18.06 ± 9.43 4.51 ± 2.02* 0.47 8.56 .03
 Orgasmic 
function
6.50 ± 3.01 7.30 ± 2.92 5.17 ± 3.31 5.99 ± 3.75 1.30 ± 0.81 −0.33 2.94 .12
 Sexual 
desire
5.00 ± 1.41 6.77 ± 1.91 5.25 ± 1.34 6.04 ± 1.97 0.70 ± 0.44 −0.18 1.59 .12
 Intercourse 
satisfaction
7.06 ± 3.89 8.78 ± 3.77 6.33 ± 4.01 6.46 ± 4.18 2.36 ± 0.97* 0.44 4.29 .02
 Overall 
satisfaction
6.50 ± 2.71 7.10 ± 2.29 6.64 ± 2.11 7.14 ± 2.41 0.05 ± 0.52 −0.99 1.09 .92
 Total 43.19 ± 18.23 52.53 ± 16.14 40.83 ± 16.73 43.81 ± 19.86 8.69 ± 4.24* 0.24 17.15 .04
Plasma TT 
(nmol/L)
7.28 ± 4.50 12.04 ± 8.46 8.07 ± 2.79 10.18 ± 6.25 0.75 ± 2.12 −3.51 5.01 .73
 (ng/dl) 209.79 ± 129.68 346.97 ± 243.80 232.56 ± 80.40 293.37 ± 180.12  
Plasma 
prolactin
 (μIU/ml)
182.68 ± 91.49 171.15 ± 90.97 174.79 ± 99.22 170.05 ± 87.95 3.18 ± 26.64 −50.34 56.72 .91
Note. aAdjustment for multiple comparisons: Bonferroni with covariate daily methadone dosage and duration of the methadone usage.  
EOT = end of treatment; CGI-SF = Clinical Global Impression Scale adapted for Sexual Function; Mal-IIEF-15 = Malay version of the International 
Index of Erectile Function 15; SDI-2-BM = Malay version of the sexual desire inventory-2; DSD = dyadic sexual desire; SSD = solitary sexual 
desire; TT = total testosterone; SD = standard deviation; SE = standard error. nmol/L = nanomoles per liter; ng/dl = nanograms per deciliter; 
μIU/ml = macro international units per milliliter.
*p < .05. **p < .01.
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Table 3. Pairwise Comparison Within Group Over Time.
Outcome measure Group (I) Time (J) Time
Mean 
differencea 
(I−J) SE p value
95% CI for differencea
Lower bound Upper bound
CGI-SF
 Placebo Baseline Week 2 0.86* 0.22 .01 0.27 1.45
 Baseline Week 4 1.21** 0.25 <.01 0.54 1.88
 Baseline Week 6 1.62** 0.26 <.01 0.91 2.33
 Bupropion Baseline Week 2 1.45*** 0.22 <.001 1.52 2.57
 Baseline Week 4 1.96*** 0.25 <.001 1.58 2.74
 Baseline Week 6 2.57*** 0.36 <.001 1.87 3.28
SDI-2-BM
 DSD Placebo Baseline Week 2 −3.51 1.49 .13 −7.56 0.54
 Baseline Week 4 −3.25 1.69 .34 −7.85 1.35
 Baseline Week 6 −2.81 1.82 .76 −7.76 2.14
 Bupropion Baseline Week 2 −7.77*** 1.49 <.001 −11.81 −3.72
 Baseline Week 4 −8.62*** 1.69 <.001 −13.22 −4.02
 Baseline Week 6 −9.41*** 1.82 <.001 −14.35 −4.46
 SSD Placebo Baseline Week 2 −1.73 0.92 .38 −4.22 0.77
 Baseline Week 4 −1.26 0.81 .73 −3.46 0.93
 Baseline Week 6 −1.86 0.83 .17 −4.11 0.40
 Bupropion Baseline Week 2 −1.48 0.92 .68 −3.97 1.02
 Baseline Week 4 −1.51 0.81 .40 −3.70 0.69
 Baseline Week 6 −1.19 0.83 .93 −3.44 1.06
 Total Placebo Baseline Week 2 −6.39 2.66 .12 −13.63 0.85
 Baseline Week 4 −5.82 2.81 .25 −13.45 1.81
 Baseline Week 6 −6.84 2.90 .13 −14.72 1.04
 Bupropion Baseline Week 2 −11.30*** 2.66 <.001 −18.54 −4.06
 Baseline Week 4 −11.56*** 2.81 <.001 −19.19 −3.94
 Baseline Week 6 −11.77*** 2.90 <.001 −19.65 −3.89
Mal-IIEF-15 domain
 Erectile function Placebo Baseline Week 2 −0.87 1.45 1.00 −4.80 3.07
 Baseline Week 4 −1.17 1.40 1.00 −4.96 2.63
 Baseline Week 6 −1.24 1.38 1.00 −5.00 2.51
 Bupropion Baseline Week 2 −1.50 1.45 1.00 −5.44 2.43
 Baseline Week 4 −2.67 1.40 .36 −6.47 1.12
 Baseline Week 6 −3.93* 1.38 .04* −7.68 −0.17
 Orgasmic function Placebo Baseline Week 2 −0.92 0.53 .53 −2.38 0.53
 Baseline Week 4 −1.40 0.56 .09 −2.92 0.13
 Baseline Week 6 −1.08 0.62 .51 −2.76 0.60
 Bupropion Baseline Week 2 0.35 0.53 1.00 −1.10 1.80
 Baseline Week 4 −0.46 0.56 1.00 −1.99 1.06
 Baseline Week 6 −0.63 0.62 1.00 −2.31 1.05
 Sexual desire Placebo Baseline Week 2 −0.20 0.27 1.00 −0.93 0.53
 Baseline Week 4 −0.49 0.29 .60 −1.29 0.31
 Baseline Week 6 −0.88 0.31 .05 −1.72 −0.06
 Bupropion Baseline Week 2 −0.86*** 0.27 <.001 −1.61 −0.16
 Baseline Week 4 −1.31*** 0.29 <.001 −2.11 −0.52
 Baseline Week 6 −1.68*** 0.31 <.001 −2.51 −0.85
 Intercourse Placebo Baseline Week 2 0.11 0.63 1.00 −1.61 1.83
 Satisfaction Baseline Week 4 −0.56 0.65 1.00 −2.34 1.22
 Baseline Week 6 −0.33 0.66 1.00 −2.12 1.46
 Bupropion Baseline Week 2 −0.37 0.63 1.00 −2.08 1.35
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Outcome measure Group (I) Time (J) Time
Mean 
differencea 
(I−J) SE p value
95% CI for differencea
Lower bound Upper bound
 Baseline Week 4 −0.72 0.65 1.00 −2.49 1.06
 Baseline Week 6 −1.63 0.66 .09 −3.42 0.16
 Overall satisfaction Placebo Baseline Week 2 −0.03 0.40 1.00 −1.10 1.04
 Baseline Week 4 −0.09 0.37 1.00 −1.09 0.92
 Baseline Week 6 −0.45 0.37 1.00 −1.46 0.56
 Bupropion Baseline Week 2 −0.57 0.40 .91 −1.65 0.50
 Baseline Week 4 −0.19 0.37 1.00 −1.20 0.81
 Baseline Week 6 −0.54 0.37 .91 −1.55 0.47
 Total Placebo Baseline Week 2 −2.66 2.86 1.00 −10.43 5.11
 Baseline Week 4 −3.89 2.65 .88 −11.10 3.31
 Baseline Week 6 −4.19 2.71 .76 −11.57 3.18
 Bupropion Baseline Week 2 −3.01 2.86 1.00 −10.78 4.76
 Baseline Week 4 −5.32 2.65 .29 −12.52 1.88
 Baseline Week 6 −8.37* 2.71 .02 −15.75 −1.00
Plasma TT (nmol/L) Placebo Baseline Week 6 −3.32 1.62 .05 −6.57 −0.07
 Bupropion Baseline Week 6 −4.03* 1.56 .01 −7.15 −0.90
Plasma prolactin (μIU/ml) Placebo Baseline Week 6 3.94 18.61 .83 −33.45 41.33
 Bupropion Baseline Week 6 13.70 17.88 .45 −22.23 49.63
Note. aAdjustment for multiple comparisons: Bonferroni with covariate daily methadone dosage and duration of the methadone usage. CGI-
SF = Clinical Global Impression Scale adapted for Sexual Function; Mal-IIEF-15 = Malay version of the International Index of Erectile Function 
15; SDI-2-BM = Malay version of the sexual desire inventory-2; DSD = dyadic sexual desire; SSD = solitary sexual desire; TT = total 
testosterone; SD, standard deviation; SE, standard error. nmol/L = nanomoles per liter; μIU/ml = macro international units per milliliter.
*p < .05. **p < .01. ***p < .001.
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Figure 3. Mean dyadic sexual desire (DSD) in methadone-
emergent sexual dysfunction patients receiving sustained-
release bupropion (bupropion SR) or placebo. *p < .05.
to CYP2B6 inhibitory drug interactions (Kharasch, 
Regina, Blood, & Friedel, 2015). Besides, bupropion 
has been demonstrated to be an effective inhibitor of 
CYP2D6 which is also involved in methadone metabo-
lism, leading to clinically significant higher methadone 
concentrations (Hedrich et al., 2016). This indicates that 
individuals who concurrently take bupropion and 
methadone will not need high dose of methadone which 
may in turn experience less side effect such as sexual 
dysfunction from methadone. Due to large inter-individ-
ual variability in methadone’s pharmacokinetics and its 
pharmacodynamics, the effect of methadone–bupropion 
interaction on sexual function and plasma testosterone 
Figure 4. Total Malay Version of International Index of 
Erectile Function mean scores (Mal-IIEF-15) in methadone-
emergent sexual dysfunction patients receiving sustained-
release bupropion (bupropion SR) or placebo. *p < .05.
1716 American Journal of Men’s Health 12(5)
remained unclear. More research is needed to determine 
the effect of methadone-bupropion interaction in sexual 
functioning.
Bupropion SR was well tolerated in this study. The 
most frequently reported adverse event in the present 
study was insomnia, which occurred with similar fre-
quency in previous studies (Aubin, 2002; Croft et al., 
1999).
Current study was not without a few limitations. The 
sample size was relatively small. Additionally, this 
study relied on patient self-report on their sexual dys-
function, which could be subjective, potentially inac-
curate due to recall bias. Besides, this study might not 
be generalizable to all MMT men who had not met the 
criteria of this study. Limitation of this trial to a 6-week 
duration was also a consideration and it was unknown 
whether bupropion SR would have been beneficial in 
the long run.
Conclusion
Despite the limitations, our results supported the effec-
tiveness of a 6-week adjunctive bupropion SR treatment. 
Bupropion SR treatment had significantly improved the 
key aspects of sexual function in men with MMT-
emergent sexual dysfunction in this study.
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